Common Stock, par value $0.001 per share
- Symbol
- BBLG
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 7.01, 9.01 · 8-K
Bone Biologics Corp
BBLGNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 23, 2026, Bone Biologics Corporation (the “Company”) issued a press release highlighting the corporate, scientific and operational milestones progress across 2026 priorities. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities →Company context
We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (“DBM”) is an osteopromotive recombinant protein that provides target specific control over bone regeneration. The NELL-1 technology platform has been licensed exclusively for worldwide applications to us through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the U.S. Food and Drug Administration (“FDA”) that NELL-1/DBM will be classified as a device/drug combination product that will require an FDA-approved pre-market approval (“PMA”) application before it can be commercialized in the United States.
Current securities
Recent company filings
- 10-Q filingOct 26, 2026
- 25-NSE - filed by Nasdaq Stock Market LLC regarding Bone Biologics CorpOct 13, 2026
- Submission of Matters to a Vote of Security HoldersSep 29, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 16, 2026
- DEF 14A filingAug 28, 2026
Registered securities in this filing
BONE BIOLOGICS CORPORATION · 8-K · Filed 2026-07-23
Warrants to Purchase Common Stock, par value $0.001 per share
- Symbol
- BBLGW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Historical · closed Oct 12, 2026
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On
July 23, 2026, Bone Biologics Corporation (the “Company”) issued a press release highlighting the corporate, scientific and
operational milestones progress across 2026 priorities. A copy of the press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The
information furnished pursuant to this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under
such section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933,
as amended, or the Exchange Act.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027 BURLINGTON, Mass., July 23, 2026 --(GLOBE NEWSWIRE)--Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today issued a shareholder update summarizing the Company’s progress through the first half of 2026, including its recently completed financing, continued advancement of NB1, its rhNELL-1-based bone graft product candidate, and further validation of its manufacturing and product stability profile. “During the first half of 2026, we strengthened several of the fundamental drivers underlying NB1’s development and long-term value proposition: clinical execution, product stability, intellectual property protection and capital visibility,” said Bone Biologics CEO Jeff Frelick. “The extension of rhNELL-1’s validated shelf life to 29 months enhances our manufacturing and supply-chai…
Open exhibit ↗